Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.
World J Psychiatry. Sep 19, 2026; 16(9): 116579
Published online Sep 19, 2026. doi: 10.5498/wjp.116579
Published online Sep 19, 2026. doi: 10.5498/wjp.116579
Efficacy and influencing factors of 3-N-Butylphthalide-trazodone combination in managing post-ischemic stroke depression
Zhi-Hua Zhu, Yong-Sen Lin, Zhu-Quan Hong, Department of Neurology, Quanzhou First Hospital, Quanzhou 362000, Fujian Province, China
Author contributions: Zhu ZH designed the research and wrote the first manuscript; Zhu ZH and Lin YS contributed to conceiving the research and analyzing data; Zhu ZH and Hong ZQ conducted the analysis and provided guidance for the research; all authors reviewed and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Medical Ethics Committee of Quanzhou First Hospital, No. [2026]K133.
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: There is no conflict of interest.
Data sharing statement: No additional data are available.
Corresponding author: Zhu-Quan Hong, Associate Chief Physician, Department of Neurology, Quanzhou First Hospital, No. 1028 Anji South Road, Fengze District, Quanzhou 362000, Fujian Province, China. 971696252@qq.com
Received: January 30, 2026
Revised: March 12, 2026
Accepted: May 8, 2026
Published online: September 19, 2026
Processing time: 205 Days and 22.3 Hours
Revised: March 12, 2026
Accepted: May 8, 2026
Published online: September 19, 2026
Processing time: 205 Days and 22.3 Hours
Core Tip
Core Tip: For the optimization of treatment for post-ischemic stroke depression, this study verified the efficacy of the 3-N-Butylphthalide (NBP)-Trazodone (TRZ) combination and explored efficacy-associated determinants. Without increasing the total incidence of adverse reactions, the NBP-TRZ combination was significantly superior to TRZ monotherapy in therapeutic efficacy, while also significantly improving patients’ neurological function and daily living ability, alleviating depression, and regulating serum neurotransmitters. Comorbid hyperlipidemia, low 5-hydroxytryptamine, reduced dopamine, and TRZ monotherapy were associated with treatment ineffectiveness in such patients.